Hepatocellular carcinoma patients with high circulating cytotoxic T cells and intra-tumoral immune signature benefit from pembrolizumab: results from a single-arm phase 2 trial

BACKGROUND: A limited number of studies have characterized genomic properties of hepatocellular carcinoma (HCC) patients in response to anti-PD-1 immunotherapy. METHODS: Herein, we performed comprehensive molecular characterization of immediate (D-42 to D-1) pre-treatment tumor biopsy specimens from...

Descripción completa

Detalles Bibliográficos
Autores principales: Hong, Jung Yong, Cho, Hee Jin, Sa, Jason K., Liu, Xiaoqiao, Ha, Sang Yun, Lee, Taehyang, Kim, Hajung, Kang, Wonseok, Sinn, Dong Hyun, Gwak, Geum-Youn, Choi, Moon Seok, Lee, Joon Hyeok, Koh, Kwang Cheol, Paik, Seung Woon, Park, Hee Chul, Kang, Tae Wook, Rhim, Hyunchul, Lee, Su Jin, Cristescu, Razvan, Lee, Jeeyun, Paik, Yong Han, Lim, Ho Yeong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8734300/
https://www.ncbi.nlm.nih.gov/pubmed/34986867
http://dx.doi.org/10.1186/s13073-021-00995-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8734300/
https://www.ncbi.nlm.nih.gov/pubmed/34986867
http://dx.doi.org/10.1186/s13073-021-00995-8

Ejemplares similares